NEW YORK (GenomeWeb) – Bio-Techne today announced a deal to buy protein analysis technology firm ProteinSimple for $300 million in cash.

The deal, which is anticipated to close on or around July 31, will be funded by Bio-Techne through cash on hand and a new revolving line of credit facility that Bio-Techne expects to obtain before the closing of the acquisition.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

The New York Times editorial board weighs in on scientific research misconduct.